BACKGROUND: Post-traumatic stress disorder (PTSD) is a multisystem neurobiological disorder with chronic alterations in various neurochemical systems. Levels of the GABA(A)--antagonistic neurosteroids plasma dehydroepiandrosterone (DHEA) and its sulphate derivate, dehydroepiandrosterone sulphate (DHEAS) may be relevant to depressive and anxiety disorders, including PTSD. METHODS: We assessed the circulatory levels of morning plasma DHEA and DHEAS in 21 male outpatients with untreated chronic combat-related PTSD (CR-PTSD), and 18 healthy control male subjects. RESULTS: Compared with the control subjects, the PTSD patients showed significantly higher plasma DHEA and DHEAS levels. CONCLUSIONS: Chronic CR-PTSD may be associated with increased circulatory level of neuroactive steroids with inhibitory activity at the GABA(A) receptors. Neurosteroid-induced decreased GABAergic tone may be relevant to the symptomatology and pathophysiology of chronic PTSD, as well as to the frequent co-morbidity of PTSD with depression and anxiety disorders.
BACKGROUND: Post-traumatic stress disorder (PTSD) is a multisystem neurobiological disorder with chronic alterations in various neurochemical systems. Levels of the GABA(A)--antagonistic neurosteroids plasma dehydroepiandrosterone (DHEA) and its sulphate derivate, dehydroepiandrosterone sulphate (DHEAS) may be relevant to depressive and anxiety disorders, including PTSD. METHODS: We assessed the circulatory levels of morning plasma DHEA and DHEAS in 21 male outpatients with untreated chronic combat-related PTSD (CR-PTSD), and 18 healthy control male subjects. RESULTS: Compared with the control subjects, the PTSDpatients showed significantly higher plasma DHEA and DHEAS levels. CONCLUSIONS: Chronic CR-PTSD may be associated with increased circulatory level of neuroactive steroids with inhibitory activity at the GABA(A) receptors. Neurosteroid-induced decreased GABAergic tone may be relevant to the symptomatology and pathophysiology of chronic PTSD, as well as to the frequent co-morbidity of PTSD with depression and anxiety disorders.
Authors: Amira Pierucci-Lagha; Jonathan Covault; Richard Feinn; Rahul T Khisti; A Leslie Morrow; Christine E Marx; Lawrence J Shampine; Henry R Kranzler Journal: Psychopharmacology (Berl) Date: 2005-12-10 Impact factor: 4.530
Authors: Rachel Yehuda; Laura C Pratchett; Matthew W Elmes; Amy Lehrner; Nikolaos P Daskalakis; Erin Koch; Iouri Makotkine; Janine D Flory; Linda M Bierer Journal: Interface Focus Date: 2014-10-06 Impact factor: 3.906
Authors: Rafaela S C Takeshita; Renata S Mendonça; Fred B Bercovitch; Michael A Huffman Journal: J Comp Physiol B Date: 2019-09-23 Impact factor: 2.200
Authors: Roger K Pitman; Ann M Rasmusson; Karestan C Koenen; Lisa M Shin; Scott P Orr; Mark W Gilbertson; Mohammed R Milad; Israel Liberzon Journal: Nat Rev Neurosci Date: 2012-10-10 Impact factor: 34.870
Authors: Allen D Radant; Dorcas J Dobie; Elaine R Peskind; M Michele Murburg; Eric C Petrie; Evan D Kanter; Murray A Raskind; Charles W Wilkinson Journal: Front Behav Neurosci Date: 2009-10-30 Impact factor: 3.558